Merck’s reinvigorated pipeline and Sanofi’s minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.
Merck’s reinvigorated pipeline and Sanofi’s minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.